中国创新药的2026：又一个全球交易的大年？

Core Viewpoint - The trend of Chinese pharmaceutical companies expanding overseas continues to gain momentum, with significant transactions and collaborations expected to persist into 2026, although the total number and value of deals may not surpass those of 2025 [3][20]. Group 1: Overseas Authorization Transactions - In January 2026, Chinese pharmaceutical companies completed 10 overseas authorization transactions, with a notable deal between Rongchang Biopharma and AbbVie involving an upfront payment of $650 million [3]. - The year 2025 marked a record for overseas authorization transactions, with 158 deals totaling $135.7 billion, representing a ten-year high in both quantity and value [7]. - Major transactions in 2025 included a $12 billion strategic cooperation between Innovent Biologics and Takeda, and a $120 billion deal between Hengrui Medicine and GSK, contributing to a total upfront payment of $7 billion for Chinese innovative drugs [8]. Group 2: Market Dynamics and Trends - The U.S. remains the primary trading partner for Chinese pharmaceutical companies, accounting for approximately 48% of all overseas authorization transactions over the past decade [11]. - The increasing urgency for multinational pharmaceutical companies to replenish their pipelines due to impending patent expirations has led to heightened interest in Chinese biotech innovations [11][20]. - China's clinical trial efficiency is significantly higher than that of the U.S., with an average patient enrollment cost of $25,000 compared to $70,000 in the U.S., and a faster enrollment rate [15]. Group 3: Future Outlook - The momentum in overseas transactions is expected to continue, with companies increasingly recognizing the value of Chinese-developed drugs [18][20]. - Despite geopolitical tensions, collaboration between Chinese and U.S. pharmaceutical companies is strengthening, driven by mutual benefits in drug development [20]. - The Chinese pharmaceutical industry is establishing a competitive edge in innovation, although achieving global leadership akin to that in solar energy or automotive sectors may take more time and patience due to the complexities of drug development [20].